First Trust NYSE Arca Biotechnology Index Fund Rating $255.34 -0.74 (-0.29%) As of 02:17 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Ratings Stock AnalysisChartHoldingsOwnershipRatingsSEC FilingsShort InterestBuy This Stock First Trust NYSE Arca Biotechnology Index Fund Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.FBT Aggregate RatingModerate Buy 2.67Holdings in FBT have an aggregate rating of Moderate Buy based on 488 analyst ratings issued in the past year covering 25 companies (86.0% of the portfolio).FBT Aggregate Price Target$255.30-0.01% DownsideHigh Prediction$255.30Average Prediction$255.30Low Prediction$255.30Holdings in FBT have an aggregate price target of $255.30 and a range of $255.30 to $255.30 covering 25 companies (86.0% of the portfolio).FBT Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy1 Buy rating(s)Moderate Buy18 Moderate Buy rating(s)Hold6 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by First Trust NYSE Arca Biotechnology Index Fund Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 25 FBT Holdings ExportWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings3.93%CORTCorcept Therapeutics$114.65+3.7%3.3707 of 5 stars2.63$119.17 3.9%8Positive NewsInsider Trade3.89%REGNRegeneron Pharmaceuticals$804.12-0.2%3.78 of 5 stars2.62$793.74 -1.3%26Insider Trade3.76%HALOHalozyme Therapeutics$98.43-2.2%3.8753 of 5 stars2.62$91.20 -7.3%13Insider Trade3.73%AMGNAmgen$413.76-1.0%3.8123 of 5 stars2.35$372.39 -10.0%31Analyst ForecastInsider Trade3.71%ADMAADMA Biologics$9.41-0.1%3.9603 of 5 stars2.33$18.67 98.5%63.70%RGENRepligen$167.24-0.2%3.1645 of 5 stars2.94$166.43 -0.5%18Positive News3.69%ONCBeOne Medicines$347.40-2.4%4.4911 of 5 stars3.00$402.14 15.8%17Insider Trade3.69%NEONeoGenomics$15.94-2.8%1.9665 of 5 stars2.73$16.71 4.9%113.48%BMRNBioMarin Pharmaceutical$67.56-1.4%4.8586 of 5 stars2.70$88.00 30.2%23Analyst Downgrade3.47%BIIBBiogen$209.99-0.3%4.0032 of 5 stars2.58$227.07 8.1%33Analyst Downgrade3.44%GMABGenmab A/S$31.92+1.9%4.4133 of 5 stars2.85$39.50 23.7%13Analyst Upgrade3.41%ILMNIllumina$191.90-0.4%3.235 of 5 stars2.47$188.40 -1.8%17Positive News3.39%INCYIncyte$120.11-0.3%3.5373 of 5 stars2.43$120.65 0.4%23Analyst Forecast3.37%GILDGilead Sciences$138.130.0%4.4525 of 5 stars2.83$158.04 14.4%29Trending NewsAnalyst DowngradeOptions VolumeAnalyst Revision3.37%TECHBio-Techne$72.25+0.1%3.196 of 5 stars2.06$68.92 -4.6%17Positive NewsEarnings ReportDividend AnnouncementAnalyst Downgrade3.34%VRTXVertex Pharmaceuticals$507.40-1.7%4.4301 of 5 stars2.92$563.50 11.1%243.34%ARGXargenex$847.96-1.0%4.7898 of 5 stars2.92$1,056.89 24.6%243.33%BNTXBioNTech$92.71+0.6%3.3454 of 5 stars2.74$127.81 37.9%193.29%NTRANatera$310.44-0.1%2.6901 of 5 stars2.82$319.38 2.9%22Analyst Forecast3.26%UTHRUnited Therapeutics$499.64-0.3%4.3613 of 5 stars2.85$646.00 29.3%13Insider TradeAnalyst Revision3.18%MDGLMadrigal Pharmaceuticals$507.48+0.0%4.0497 of 5 stars2.78$689.93 36.0%18Positive News3.12%ALKSAlkermes$49.20-0.5%3.1203 of 5 stars2.72$54.56 10.9%18Positive News3.09%EXELExelixis$50.99+0.8%3.1116 of 5 stars2.32$49.79 -2.4%19Analyst UpgradeInsider Trade3.02%NBIXNeurocrine Biosciences$153.10+1.5%4.9877 of 5 stars2.88$200.86 31.2%24Analyst Downgrade3.01%AXSMAxsome Therapeutics$215.78+1.0%3.2561 of 5 stars2.82$267.60 24.0%22Earnings ReportAnalyst Forecast This page (NYSEARCA:FBT) was last updated on 8/14/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...Porter & Company | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"The US just hit $39 trillion in debt. Interest alone is now over $1 trillion a year, more than the entire defe...Decentralized Masters | SponsoredWhy I'm sending this one to my own familyBehind the Markets editor Kelly Maguire says she has never sent an email quite like this one. A sealed congres...Behind the Markets | SponsoredCentral banks bought 710 tonnes - this fund pays monthlyGold is hitting new highs, fueled by tariffs and record central bank demand - 710 tonnes per quarter. JPMorgan...Investors Alley | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredGold buyout deals have handed shareholders overnight gains up to 79 percentGold major acquisitions have repriced junior miners overnight, with past deals delivering gains from 40% to 1,...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding First Trust NYSE Arca Biotechnology Index Fund Please log in to your account or sign up in order to add this asset to your watchlist. Share First Trust NYSE Arca Biotechnology Index Fund With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
